NIBSC has a portfolio of reference and research reagents to support areas of diagnostics, vaccine development and research on COVID-19 and SARS-CoV-2.

Details are provided below to guide you to the materials most suitable to your needs. Further information is available in the Instructions for Use document associated with each material which can be accessed by clicking on the relevant NIBSC code.


Available now

To order any of these reagents, please first ensure that you have set up an account with us and then select the NIBSC code from the list below.

Anti-SARS-CoV-Verification Panel for Serology Assays  (NIBSC code: 20/B770)

Material:  Antibody, human, convalescent plasma Anti-SARS-CoV-2 negative plasma
Intended use: Diagnostics laboratories, Assay manufacturers
Description: Anti-SARS-CoV-2 Verification Panel for Serology Assays. Contains 23 Ant-SARS-CoV-2 positive samples of varying reactivity and antibody composition & 14 Anti-SARS-CoV-2 negative samples. The panel is CE-marked under ISO 13485 and is intended to verify manufacturer’s claims in compliance with ISO 15189.
Enquiriesdiagnostics@nibsc.org

Anti-SARS-CoV-2 Antibody Diagnostic Calibrant (NIBSC code: 20/162)

Material:  Antibody, human, convalescent plasma
Intended use: Diagnostic laboratories, Assay manufacturers, Diagnostic Serological Calibrant
Description: High titre Anti-SARS-CoV-2 antibody positive material used to assess and compare the relative sensitivities for Anti-Sars-CoV-2 antibody assays by end-point dilution.
Enquiries: diagnostics@nibsc.org

External Quality Control reagent for anti-SARS-CoV-2 antibody (NIBSC code: 20/B764)

Material: Antibody, human, convalescent plasma, CE-marked
Intended use: Diagnostics laboratories Quality Control reagent 
Description: External Quality Control to monitor the assay performance, equipment and operators on a run to run or day to day basis. CE marked under ISO 13485. Fulfils the requirements of a reference material as described in ISO 15189.
Enquiriesdiagnostics@nibsc.org

CE-marked SARS-CoV-2 NAT reagent (NIBSC code: 20/110)

Material: RNA, armoured, CE-marked.
Intended use: Diagnostics laboratories - Run control designed to ensure the fidelity and reproducibility of molecular assays.
Description: In-assay performance monitoring of both the assay and operators on a day to day basis. CE marked under ISO 13485. Fulfils the requirements of a reference material as described in ISO 15189. 
Enquiriesdiagnostics@nibsc.org

Research reagent for SARS-CoV-2 RNA (NIBSC code: 19/304

Material: RNA, armoured
Intended use: Assay development, Research - Molecular assay development; positive control for nucleic acid amplification-based assays.
DescriptionChimaeric HIV-like particles containing SARS-CoV-2 RNA, formulated in a TRIS buffer with human serum albumin and trehalose. Non-infectious. Requires extraction prior to downstream amplification. 
Enquiriesstandards@nibsc.org

Research reagent for anti-SARS-CoV-2 Ab (NIBSC code: 20/130)

Material: Antibody, human, convalescent plasma
Intended use: Assay development, Research - Serological assay development and evaluation; positive control for assays detecting antibodies.
Description: Convalescent plasma from recovered COVID-19 patient, containing high titre antibodies against SARS-CoV-2.  Plasma has been solvent detergent treated to minimise the risk of presence of enveloped viruses.
Enquiriesstandards@nibsc.org


Coming soon

1st WHO International Standard for SARS-CoV-2 RNA

Material: RNA, WHO IS
Intended use: Primary calibrant for molecular assays
Anticipated delivery date: December 2020
EnquiriesGiada.Mattiuzzo@nibsc.org

1st WHO International Standard for anti-SARS-CoV-2 antibody

Material: Antibody, human, convalescent plasma, WHO IS 
Intended usePrimary calibrant for serological assays
Anticipated delivery date: December 2020
EnquiriesGiada.Mattiuzzo@nibsc.org

WHO Reference Panel for anti-SARS-CoV-2 antibodies

Material: Antibody, human, convalescent plasma, WHO reference panel
Intended use
Assay development, Vaccine evaluation, Research, Serological assay development and evaluation
Anticipated delivery date: December 2020
EnquiriesGiada.Mattiuzzo@nibsc.org


Related Materials

The materials listed below are available from the Centre for Aids Reagents (CFAR) and can be ordered following the completion of a Material Transfer Agreement. Please contact cfar@nibsc.org if you require assistance or have any additional enquiries about these materials.

Purified RNA extracts from BetaCoV/Australia/VIC01/2020 (CFAR#100988)

Material: RNA
Intended use: Research

BetaCoV/Australia/VIC01/2020 (inactivated) (CFAR#100987)

Material: Virus, inactivated
Intended use: Research

BetaCoV/Australia/VIC01/2020 (CFAR #100980)

Material: Virus, infectious
Intended use: Research

SARS-CoV-2 S1 (CFAR #100979)

Material: Protein
Intended use: Research

SARS-CoV-2 N (CFAR #100982)

Material: Protein
Intended use: 
Research

pCAGGS_SARS-CoV-2_Spike (CFAR #100976)

Material: Plasmid
Intended use: 
Research

pCAGGS_SARS_CoV2_D614G_Spike (CFAR #100985)

Material: Plasmid
Intended use: Research

pCAGGS_SARS_CoV2_Bristol-Deletion_Spike (CFAR #100986)

Material: Plasmid
Intended use: Research

VeroE6/TMPRSS2 (CFAR #100978)

MaterialCell line
Intended use: 
Research

SARS-CoV-1 S1 (CFAR#0688)

Material: Protein
Intended use: Research

Rabbit antiserum to SARS-CoV-1 S1 (CFAR #4024)

Material: Antibody
Intended use: Research